Dear readers,
Welcome to our report dedicated to the latest on stem cells. Within these pages, you will find the latest advancements in the field. We explore Alzheimer’s disease, a frontier in medical science is illuminating a glimmer of hope. Alongside the suitability of NK cells for cancer therapy which has been challenged by some investor and business interests because of limited efficacy data.
Expert insights
- Dr Andy Bader, Biotech Executive, Triumvira
- Dr Aleta Pupovac, Publications Officer, Cartherics
- Professor Alan Trounson AO, CEO, Executive Director, Cartherics
- Dr Huimin Cao, Senior Research Fellow, Cartherics
- Dr Kimberley Rockley, Senior Scientist at ApconiX
In this report, we further look at human derived induced pluripotent stem cells (hiPSCs) which have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution.
We are committed to providing you with the highest quality content, and we believe that this report will deliver a different perspective on the topics covered.
Thank you for your continued support.
Sincerely,
Taylor Mixides
Editor
Drug Target Review
